Nalaganje...
Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
BACKGROUND/AIMS: A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD activity score (NAS) after treatment with cholesterol lowering agents in NAFLD...
Shranjeno v:
| izdano v: | Korean J Intern Med |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
The Korean Association of Internal Medicine
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6406097/ https://ncbi.nlm.nih.gov/pubmed/29551054 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3904/kjim.2017.194 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|